Table 1. Characteristics of the study participants at study entry and comparison between patients with and without COVID-19.a .
| Characteristic | Total | Group | p* | |
|---|---|---|---|---|
| COVID-19 | No COVID-19 | |||
| (N = 98) | (n = 17) | (n = 81) | ||
| Age, years | 29.2 ± 8.8 | 28.2 ± 9.3 | 29.4 ± 8.72 | 0.598 |
| Sex | 0.500 | |||
| Male | 32 (33) | 2 (6) | 30 (94) | |
| Ethnicity | 1.000 | |||
| White | 98 (100) | 17 (17.5) | 81 (82.6) | |
| Age at CF diagnosis | 3 (0-17) | 8 (0-23) | 3 (0-17) | 0.652 |
| BMI, kg/m2 | 21.7 ± 2.7 | 19.8 ± 2.5 | 22.1 ± 2.6 | 0.001 |
| F508del mutation | 0.028 | |||
| Homozygous | 21 (21) | 5 (24) | 16 (76) | |
| Heterozygous | 33 (34) | 1 (3)† | 32 (97)† | |
| Other | 44 (45) | 11 (25) | 33 (75) | |
| Pancreatic insufficiency | 77 (79) | 12 (16) | 65 (84) | 0.515 |
| CFRD | 24 (25) | 2 (8) | 22 (92) | 0.228 |
| Pneumothorax | 1 (1) | 0 | 1 (100) | 1.000 |
| Massive hemoptysis (> 100 mL) | 19 (19) | 4 (21) | 15 (79) | 0.736 |
| Bronchial artery embolization | 8 (8) | 2 (25) | 6 (75) | 0.624 |
| ABPA | 17 (17.3) | 3 (17.6) | 14 (82.4) | 1.000 |
| CF-related liver disease | 28 (30) | 5 (18) | 23 (82) | 1.000 |
| Liver transplantation | 1 (1) | 0 | 1 (100) | 1.000 |
| Lung transplantation | 4 (4) | 0 | 4 (100) | 1.000 |
| Pseudomonas aeruginosa | 67 (70) | 12 (18) | 55(82) | 0.770 |
| MSSA | 60 (62) | 11 (18) | 49 (82) | 0.777 |
| MRSA | 9 (9.4) | 1 (11) | 8 (89) | 1.000 |
| Burkholderia cepacia | 22 (23) | 4 (18) | 18 (82) | 0.757 |
| MNT | 6 (6.3) | 0 | 6 (100) | 0.585 |
| Dornase alpha | 84 (86) | 13 (15.5) | 71 (84.5) | 0.257 |
| Inhaled colistimethate sodium | 51(52) | 7 (13.7) | 44 (86) | 0.472 |
| Inhaled tobramycin | 33 (34) | 5 (15) | 28 (85) | 0.899 |
| Azithromycin | 75 (76.5) | 13 (17) | 62 (83) | 1.000 |
| FVC, % predicted | 75.5 ± 21.8 | 73.9 ± 20.0 | 75.9 ± 22.3 | 0.740 |
| FEV1, % predicted | 59.3 ± 25.2 | 60.9 ± 28.1 | 59.0 ± 24.7 | 0.779 |
| FEV1/FVC, % | 76.9 ± 16.1 | 77.5 ± 21.1 | 76.8 ± 15.0 | 0.877 |
| SpO2, % | 94 (2.5) | 95 (2.8) | 94 (2.5) | 0.239 |
| 6MWD, % predicted | 69.81 ± 13.47 | 64.36 ± 12.89 | 70.94 ± 13.43 | 0.142 |
CF: cystic fibrosis; CFRD: cystic fibrosis-related diabetes; ABPA: allergic bronchopulmonary aspergillosis; MSSA: methicillin-susceptible Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus; NTM: nontuberculous mycobacteria; and 6MWD: six-minute walk distance. aData are presented as n (%), median ± SD, or median (IQR). *Chi-square test for categorical variables. Student’s t-test or Mann-Whitney U test for continuous variables. †Adjusted standard residual > 1.96 or < −1.96 (implies significantly different proportions).